Solid Biosciences (SLDB) Cash & Equivalents (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Cash & Equivalents data on file, last reported at $297.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 41.05% year-over-year to $297.1 million; the trailing twelve-month figure through Mar 2026 stood at $297.1 million (up 41.05% YoY), and the FY2025 full-year result was $59.9 million, down 25.34% from the prior year.
• Cash & Equivalents improved to $297.1 million in Q1 2026, from $59.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $297.1 million in Q1 2026 to a low of $48.8 million in Q3 2022.
• A 5-year average of $111.4 million and a median of $91.6 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 72.93% in 2022 and jumped 79.15% in 2025, its largest moves.
• Tracing SLDB's Cash & Equivalents over 5 years: stood at $155.4 million in 2022, then slumped by 52.37% to $74.0 million in 2023, then advanced by 8.4% to $80.2 million in 2024, then slipped by 25.34% to $59.9 million in 2025, then jumped by 395.99% to $297.1 million in 2026.
• Business Quant data shows SLDB's Cash & Equivalents at $297.1 million in Q1 2026, $59.9 million in Q4 2025, and $61.4 million in Q3 2025.